The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2020 | CD8+ T cell expansion in CLL patients treated with ibrutinib
Maria Joao Baptista, PharmD, PhD, Josep Carreras Leukaemia Research Institute, Barcelona, Spain, highlights the results of a study evaluating the T-cell repertoire in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. Ibrutinib was found to induce a more oligoclonal T cell receptor (TCR) repertoire in patients with chronic lymphocytic leukemia (CLL), driven by expansion of specific CD8+ clonotypes. This study supports the investigation of therapeutic strategies combining ibrutinib with T- cell-directed immunotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
